|
Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Technical Data
| Formula | C26H32N4O4S |
|||
| Molecular Weight | 496.62 | CAS No. | 475086-01-2 | |
| Solubility (25°C)* | In vitro | DMSO | 99 mg/mL (199.34 mM) | |
| Ethanol | 19 mg/mL (38.25 mM) | |||
| Water | Insoluble | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
||||
Preparing Stock Solutions
Biological Activity
| Description | Selexipag (NS-304, ACT-293987) is an orally active, first-in-class, selective prostacyclin IP receptor agonist with Ki value of 260 nM for human IP, whereas Ki values > 10,000 nM are measured at the other human G-protein-coupled prostanoid receptors (EP1-4, DP, FP and TP). | |
|---|---|---|
| Targets |
|
|
| In vitro | Selexipag is an orally available, selective IP receptor agonist. It is rapidly hydrolysed in the hepatic microsomes to an active metabolite. Selexipag and its active metabolite have a higher binding affinity for the human IP receptor than for any other prostanoid receptor[1]. | |
| In vivo | As selexipag is rapidly hydrolysed in the liver to the active metabolite, peak-trough fluctuations in serum levels of active compound may be reduced, thereby reducing the likelihood of adverse events. Thus, Selexipag is well tolerated, with a safety profile in line with that of the expected pharmacological effect[1]. Selexipag has a half-life of 0.8-2.5 hours[2]. |
Protocol (from reference)
References
|
Selleck's Selexipag has been cited by 2 publications
| Selexipag improves Lipopolysaccharide-induced ARDS on C57BL/6 mice by modulating the cAMP/PKA and cAMP/Epac1 signaling pathways [ Biol Pharm Bull, 2022, 10.1248/bpb.b21-01057] | PubMed: 35598975 |
| Novel Targets in a High-Altitude Pulmonary Hypertension Rat Model Based on RNA-seq and Proteomics [ Front Med (Lausanne), 2021, 8:742436] | PubMed: 34805208 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.